Ullrich Evelyn, Koch Joachim, Cerwenka Adelheid, Steinle Alexander
Children's Hospital; Department of Pediatric Hematology and Oncology; Goethe-University Frankfurt am Main; Frankfurt am Main, Germany ; Center for Cell and Gene Therapy; Goethe University Frankfurt am Main; Frankfurt am Main, Germany.
Center for Cell and Gene Therapy; Goethe University Frankfurt am Main; Frankfurt am Main, Germany ; Institute for Biomedical Research: Georg-Speyer-Haus; NK Cell Biology; Frankfurt am Main, Germany.
Oncoimmunology. 2013 Oct 1;2(10):e26097. doi: 10.4161/onci.26097. Epub 2013 Oct 25.
The activating immunoreceptor NKG2D endows cytotoxic lymphocytes with the capacity to recognize and eliminate infected or malignant cells. The recognition of such harmful cells is enabled by binding of NKG2D to various MHC class I-related glycoproteins, which are upregulated in the course of viral infection or malignant transformation. The past years have witnessed substantial progress in our understanding of the mechanisms underlying the regulation of NKG2D ligands (NKG2DLs) by malignant cells, of tumor-associated countermeasures promoting escape from NKG2D-dependent immunosurveillance, and of therapeutic measures that may bolster the NKG2D/NKG2DL system against malignancies. Here, we summarize the current knowledge on the NKG2D/NKG2DL system and outline opportunities to exploit the tumoricidal function of NKG2D for anticancer immunotherapy.
激活型免疫受体NKG2D赋予细胞毒性淋巴细胞识别和清除受感染或恶性细胞的能力。NKG2D与多种I类主要组织相容性复合体（MHC）相关糖蛋白结合，从而实现对这类有害细胞的识别，这些糖蛋白在病毒感染或恶性转化过程中上调。在过去几年里，我们对恶性细胞调控NKG2D配体（NKG2DLs）的潜在机制、促进肿瘤逃避NKG2D依赖性免疫监视的肿瘤相关对策以及可能增强NKG2D/NKG2DL系统对抗恶性肿瘤的治疗措施有了实质性的认识。在此，我们总结了目前关于NKG2D/NKG2DL系统的知识，并概述了利用NKG2D的杀肿瘤功能进行抗癌免疫治疗的机会。
